Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 192

1.

Can breast cancer be prevented?

Boone CW.

Ann Saudi Med. 1999 May-Jun;19(3):276. No abstract available.

2.

Tissue self-affinity and polarized light scattering in the born approximation: a new model for precancer detection.

Hunter M, Backman V, Popescu G, Kalashnikov M, Boone CW, Wax A, Gopal V, Badizadegan K, Stoner GD, Feld MS.

Phys Rev Lett. 2006 Sep 29;97(13):138102. Epub 2006 Sep 28.

PMID:
17026078
3.

Prospective grading of neoplastic change in rat esophagus epithelium using angle-resolved low-coherence interferometry.

Wax A, Pyhtila JW, Graf RN, Nines R, Boone CW, Dasari RR, Feld MS, Steele VE, Stoner GD.

J Biomed Opt. 2005 Sep-Oct;10(5):051604.

4.

Induction of invasive mouse skin carcinomas in transgenic mice with mutations in both H-ras and p53.

Zhang Z, Yao R, Li J, Wang Y, Boone CW, Lubet RA, You M.

Mol Cancer Res. 2005 Oct;3(10):563-74.

5.

Biologic evaluation of curcumin and structural derivatives in cancer chemoprevention model systems.

Gafner S, Lee SK, Cuendet M, Barthélémy S, Vergnes L, Labidalle S, Mehta RG, Boone CW, Pezzuto JM.

Phytochemistry. 2004 Nov;65(21):2849-59.

PMID:
15501252
6.

Prostate intraepithelial neoplasia in Noble rats, a potential intermediate endpoint for chemoprevention studies.

Christov KT, Moon RC, Lantvit DD, Boone CW, Kelloff GJ, Steele VE, Lubet RA, Pezzuto JM.

Eur J Cancer. 2004 Jun;40(9):1404-11.

PMID:
15177500
7.

Spectroscopic diagnosis and imaging of invisible pre-cancer.

Badizadegan K, Backman V, Boone CW, Crum CP, Dasari RR, Georgakoudi I, Keefe K, Munger K, Shapshay SM, Sheetse EE, Feld MS.

Faraday Discuss. 2004;126:265-79; discussion 303-11.

PMID:
14992412
8.

In situ detection of neoplastic transformation and chemopreventive effects in rat esophagus epithelium using angle-resolved low-coherence interferometry.

Wax A, Yang C, Müller MG, Nines R, Boone CW, Steele VE, Stoner GD, Dasari RR, Feld MS.

Cancer Res. 2003 Jul 1;63(13):3556-9.

9.

Spectroscopic detection and evaluation of morphologic and biochemical changes in early human oral carcinoma.

Müller MG, Valdez TA, Georgakoudi I, Backman V, Fuentes C, Kabani S, Laver N, Wang Z, Boone CW, Dasari RR, Shapshay SM, Feld MS.

Cancer. 2003 Apr 1;97(7):1681-92.

11.

9-cis-retinoic acid but not 4-(hydroxyphenyl)retinamide inhibits prostate intraepithelial neoplasia in Noble rats.

Christov KT, Moon RC, Lantvit DD, Boone CW, Steele VE, Lubet RA, Kelloff GJ, Pezzuto JM.

Cancer Res. 2002 Sep 15;62(18):5178-82.

12.

Cellular organization and substructure measured using angle-resolved low-coherence interferometry.

Wax A, Yang C, Backman V, Badizadegan K, Boone CW, Dasari RR, Feld MS.

Biophys J. 2002 Apr;82(4):2256-64.

13.

NAD(P)H and collagen as in vivo quantitative fluorescent biomarkers of epithelial precancerous changes.

Georgakoudi I, Jacobson BC, Müller MG, Sheets EE, Badizadegan K, Carr-Locke DL, Crum CP, Boone CW, Dasari RR, Van Dam J, Feld MS.

Cancer Res. 2002 Feb 1;62(3):682-7.

14.

How curcumin works preferentially with water soluble antioxidants.

Jovanovic SV, Boone CW, Steenken S, Trinoga M, Kaskey RB.

J Am Chem Soc. 2001 Apr 4;123(13):3064-8.

PMID:
11457017
15.

Quantitative nuclear morphometry by image analysis for prediction of recurrence of ductal carcinoma in situ of the breast.

Hoque A, Lippman SM, Boiko IV, Atkinson EN, Sneige N, Sahin A, Weber DM, Risin S, Lagios MD, Schwarting R, Colburn WJ, Dhingra K, Follen M, Kelloff GJ, Boone CW, Hittelman WN.

Cancer Epidemiol Biomarkers Prev. 2001 Mar;10(3):249-59.

16.

Chromosome 3p tumor-suppressor gene alterations in cervical carcinomas.

Herzog CR, Crist KA, Sabourin CL, Kelloff GJ, Boone CW, Stoner GD, You M.

Mol Carcinog. 2001 Mar;30(3):159-68.

PMID:
11301476
17.

Computer-assisted image analysis-derived intermediate endpoints.

Boone CW, Lieberman R, Mairinger T, Palcic B, Bacus J, Bartels P.

Urology. 2001 Apr;57(4 Suppl 1):129-31.

PMID:
11295610
18.

Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer.

Kelloff GJ, Lieberman R, Steele VE, Boone CW, Lubet RA, Kopelovich L, Malone WA, Crowell JA, Higley HR, Sigman CC.

Urology. 2001 Apr;57(4 Suppl 1):46-51.

PMID:
11295594
19.

Detection of genetic alterations in mouse lung adenocarcinomas by two-dimensional gel electrophoresis.

Liu J, Gu P, Bergman G, Kelloff GJ, Boone CW, You M, Wang Y.

Exp Lung Res. 2000 Dec;26(8):651-8.

PMID:
11195462
20.

Chemoprevention with theaflavins of rat esophageal intraepithelial neoplasia quantitatively monitored by image tile analysis.

Boone CW, Stoner GD, Bacus JV, Kagan V, Morse MA, Kelloff GJ, Bacus JW.

Cancer Epidemiol Biomarkers Prev. 2000 Nov;9(11):1149-54.

21.

Quantitative grading of rat esophageal carcinogenesis using computer-assisted image tile analysis.

Boone CW, Stoner GD, Bacus JV, Kagan V, Morse MA, Kelloff GJ, Bacus JW.

Cancer Epidemiol Biomarkers Prev. 2000 May;9(5):495-500.

23.

Progress in cancer chemoprevention: development of diet-derived chemopreventive agents.

Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Malone WA, Boone CW, Kopelovich L, Hawk ET, Lieberman R, Lawrence JA, Ali I, Viner JL, Sigman CC.

J Nutr. 2000 Feb;130(2S Suppl):467S-471S. doi: 10.1093/jn/130.2.467S. Review.

PMID:
10721931
24.

Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer.

Kelloff GJ, Sigman CC, Johnson KM, Boone CW, Greenwald P, Crowell JA, Hawk ET, Doody LA.

Cancer Epidemiol Biomarkers Prev. 2000 Feb;9(2):127-37. Review.

25.

Progress in cancer chemoprevention.

Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Boone CW, Malone WA, Hawk ET, Lieberman R, Lawrence JA, Kopelovich L, Ali I, Viner JL, Sigman CC.

Ann N Y Acad Sci. 1999;889:1-13. Review.

PMID:
10668477
26.

Image morphometric nuclear grading of intraepithelial neoplastic lesions with applications to cancer chemoprevention trials.

Bacus JW, Boone CW, Bacus JV, Follen M, Kelloff GJ, Kagan V, Lippman SM.

Cancer Epidemiol Biomarkers Prev. 1999 Dec;8(12):1087-94.

27.

Comparative chemopreventive mechanisms of green tea, black tea and selected polyphenol extracts measured by in vitro bioassays.

Steele VE, Kelloff GJ, Balentine D, Boone CW, Mehta R, Bagheri D, Sigman CC, Zhu S, Sharma S.

Carcinogenesis. 2000 Jan;21(1):63-7.

PMID:
10607735
29.

Chemoprevention of prostate cancer: concepts and strategies.

Kelloff GJ, Lieberman R, Steele VE, Boone CW, Lubet RA, Kopelovitch L, Malone WA, Crowell JA, Sigman CC.

Eur Urol. 1999;35(5-6):342-50. Review.

PMID:
10325487
30.

Preclinical efficacy studies of green and black tea extracts.

Steele VE, Bagheri D, Balentine DA, Boone CW, Mehta R, Morse MA, Sharma S, Sigman CC, Stoner GD, Wargovich MJ, Weisburger JH, Zhu S, Kelloff GJ.

Proc Soc Exp Biol Med. 1999 Apr;220(4):210-2. Review. No abstract available.

PMID:
10202390
31.

Preclinical drug development paradigms for chemopreventives.

Steele VE, Boone CW, Lubet RA, Crowell JA, Holmes CA, Sigman CC, Kelloff GJ.

Hematol Oncol Clin North Am. 1998 Oct;12(5):943-61, v-vi. Review.

PMID:
9888015
32.

Oltipraz, a novel inhibitor of hepatitis B virus transcription through elevation of p53 protein.

Chi WJ, Doong SL, Lin-Shiau SY, Boone CW, Kelloff GJ, Lin JK.

Carcinogenesis. 1998 Dec;19(12):2133-8.

PMID:
9886568
33.

Protective action of plant polyphenols on radiation-induced chromatid breaks in cultured human cells.

Parshad R, Sanford KK, Price FM, Steele VE, Tarone RE, Kelloff GJ, Boone CW.

Anticancer Res. 1998 Sep-Oct;18(5A):3263-6.

PMID:
9858893
34.
35.

Development of new cancer chemoprevention agents: role of pharmacokinetic/pharmacodynamic and intermediate endpoint biomarker monitoring.

Lieberman R, Crowell JA, Hawk ET, Boone CW, Sigman CC, Kelloff GJ.

Clin Chem. 1998 Feb;44(2):420-7.

36.

Properties of intraepithelial neoplasia relevant to cancer chemoprevention and to the development of surrogate end points for clinical trials.

Boone CW, Bacus JW, Bacus JV, Steele VE, Kelloff GJ.

Proc Soc Exp Biol Med. 1997 Nov;216(2):151-65. Review.

PMID:
9349684
37.

Aromatase inhibitors as potential cancer chemopreventives.

Kelloff GJ, Lubet RA, Lieberman R, Eisenhauer K, Steele VE, Crowell JA, Hawk ET, Boone CW, Sigman CC.

Cancer Epidemiol Biomarkers Prev. 1998 Jan;7(1):65-78. Review.

38.

Effect of tea extracts, polyphenols, and epigallocatechin gallate on azoxymethane-induced colon cancer.

Weisburger JH, Rivenson A, Aliaga C, Reinhardt J, Kelloff GJ, Boone CW, Steele VE, Balentine DA, Pittman B, Zang E.

Proc Soc Exp Biol Med. 1998 Jan;217(1):104-8.

PMID:
9421213
39.

DNA image cytometric measurement as a surrogate end point biomarker in a phase I trial of alpha-difluoromethylornithine for cervical intraepithelial neoplasia.

Boiko IV, Mitchell MF, Pandey DK, White RA, Hu W, Malpica A, Nishioka K, Boone CW, Atkinson EN, Hittelman WN.

Cancer Epidemiol Biomarkers Prev. 1997 Oct;6(10):849-55.

40.

Progress in clinical chemoprevention.

Kelloff GJ, Hawk ET, Karp JE, Crowell JA, Boone CW, Steele VE, Lubet RA, Sigman CC.

Semin Oncol. 1997 Apr;24(2):241-52. Review.

PMID:
9129692
41.

Farnesyl protein transferase inhibitors as potential cancer chemopreventives.

Kelloff GJ, Lubet RA, Fay JR, Steele VE, Boone CW, Crowell JA, Sigman CC.

Cancer Epidemiol Biomarkers Prev. 1997 Apr;6(4):267-82. Review.

42.

Quantitation of preinvasive neoplastic progression in animal models of chemical carcinogenesis.

Bacus JW, Bacus JV, Stoner GD, Moon RC, Kelloff GJ, Boone CW.

J Cell Biochem Suppl. 1997;28-29:21-38.

PMID:
9589347
43.

Properties of intraepithelial neoplasia relevant to the development of cancer chemopreventive agents.

Boone CW, Bacus JW, Bacus JV, Steele VE, Kelloff GJ.

J Cell Biochem Suppl. 1997;28-29:1-20. Review.

PMID:
9589346
44.

Effects of theaflavins on N-nitrosomethylbenzylamine-induced esophageal tumorigenesis.

Morse MA, Kresty LA, Steele VE, Kelloff GJ, Boone CW, Balentine DA, Harbowy ME, Stoner GD.

Nutr Cancer. 1997;29(1):7-12.

PMID:
9383778
45.

Biomarker end-points in cancer chemoprevention trials.

Boone CW, Kelloff GJ.

IARC Sci Publ. 1997;(142):273-80. Review.

PMID:
9354926
46.

Perspectives and progress in development of breast cancer chemopreventive drugs.

Kelloff GJ, Boone CW, Crowell JA, Nayfield SG, Hawk ET, Steele VE, Lubet RA, Sigman CC.

Prog Clin Biol Res. 1997;396:159-83. Review. No abstract available.

PMID:
9108597
47.

Perspectives on chemoprevention agent selection and short-term clinical prevention trials.

Kelloff GJ, Hawk ET, Crowell JA, Boone CW, Steele VE, Lubet RA, Sigman CC.

Eur J Cancer Prev. 1996 Dec;5 Suppl 2:79-85. No abstract available.

PMID:
9061299
48.

Apoptosis, cell replication, and Western-style diet-induced tumorigenesis in mouse colon.

Risio M, Lipkin M, Newmark H, Yang K, Rossini FP, Steele VE, Boone CW, Kelloff GJ.

Cancer Res. 1996 Nov 1;56(21):4910-6.

49.

Strategies for identification and clinical evaluation of promising chemopreventive agents.

Kelloff GJ, Hawk ET, Crowell JA, Boone CW, Nayfield SG, Perloff M, Steele VE, Lubet RA.

Oncology (Williston Park). 1996 Oct;10(10):1471-84; discussion 1484-8. Review.

50.

Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives.

Kelloff GJ, Fay JR, Steele VE, Lubet RA, Boone CW, Crowell JA, Sigman CC.

Cancer Epidemiol Biomarkers Prev. 1996 Aug;5(8):657-66. Review.

Supplemental Content

Loading ...
Support Center